Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Chikungunya virus (CHIKV) replication machinery is a multi-protein complex derived from the non-structural polyprotein, which is cleaved into four essential subunits: nsP1, nsP2, nsP3, and nsP4 (UniProt: P0C2P5). This complex is responsible for the synthesis of viral genomic and subgenomic RNA within the host cell cytoplasm (PubMed: 32824354). nsP1 is involved in RNA capping and membrane anchoring, nsP2 acts as a protease and helicase, nsP3 facilitates host-protein interactions, and nsP4 serves as the primary RNA-dependent RNA polymerase (PubMed: 29456131). As these enzymes are critical for viral survival and lack human orthologs, they represent high-value therapeutic targets for treating Chikungunya fever (NCBI: NBK537333). Current drug discovery efforts target these proteins to inhibit viral load and alleviate the debilitating joint pain associated with infection (PubMed: 31433746).
Inhibition of viral RNA-dependent RNA polymerase (RdRp) activity, inhibition of nsP2 protease-mediated polyprotein cleavage, or interference with nsP1-mediated RNA capping (PubMed: 29456131).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chikungunya virus non-structural polyprotein (CHIKV nsP).